Across CDCA2, CDCA3, CDCA4, CDCA5, CDCA7, and CDCA8, we observed significantly lower promoter methylation levels in primary tumor samples compared to normal samples, suggesting hypomethylation of these genes in GBM tumors (Fig. 5A). This evidence concerns the gene CDCA8 and glioblastoma.